Integer (ITGR) 2024 Wells Fargo Healthcare Conference summary

Market environment and growth outlook

• Reported sales guidance raised to 9%-11% growth for 2024, with 6%-8% organic growth; first half delivered 9.3% reported and 7.2% organic growth in the medical segment.

• Second half sales expected to accelerate due to increased guidewire manufacturing capacity and customer product launches, especially in electrophysiology and structural heart.

• Emerging customer PMA sales on track for $100M-$120M, with growth weighted toward the second half.

• No significant changes in customer demand or market conditions compared to the start of the year.

• Long-term organic growth target remains 6%-8%, outpacing the 4%-6% market growth rate.

Operational drivers and capacity expansion

• 80,000 sq. ft. expansion in Ireland adds 70% more guidewire manufacturing capacity, enabling fulfillment of previously unmet demand.

• Non-medical business, 2% of sales, was a drag in the first half but expected to stabilize in the second half.

• Backlog visibility is strong, with nearly $900M in customer orders and detailed rolling 12-month forecasts from clients.

• Guidewire order book extends into 2025, with plans to normalize lead times as capacity increases.

Profitability and margin trends

• Operating margin grew 23% year-over-year in the first half, with full-year guidance at 18% growth, following 26% growth last year.

• Margin improvement driven by operational leverage and efficiency initiatives; tougher comps expected in the second half.

• Focus on expanding margins through Lean Six Sigma and Kaizen-based manufacturing improvements.

• Confident in returning to pre-pandemic margin levels and exceeding them over time.